MSI-H COLORECTAL CANCER
Clinical trials for MSI-H COLORECTAL CANCER explained in plain language.
Never miss a new study
Get alerted when new MSI-H COLORECTAL CANCER trials appear
Sign up with your email to follow new studies for MSI-H COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new nucleotide analogue boost cancer treatment?
Disease control TerminatedThis trial is testing an experimental drug called NUC-3373, a nucleotide analogue, in combination with standard cancer drugs for people with advanced solid tumors. The study has two parts: one combining NUC-3373 with pembrolizumab, and the other combining it with docetaxel. The g…
Matched conditions: MSI-H COLORECTAL CANCER
Phase: PHASE1, PHASE2 • Sponsor: NuCana plc • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Colon cancer combo trial ends early – only one patient enrolled
Disease control TerminatedThis study tested a combination of two drugs (regorafenib and pembrolizumab) for people with a specific type of advanced colorectal cancer called MSI-H. The goal was to see if the combination worked better than pembrolizumab alone. The trial was stopped early after enrolling only…
Matched conditions: MSI-H COLORECTAL CANCER
Phase: PHASE2 • Sponsor: Anwaar Saeed • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC